In the case of ovarian cancer ... approach holds promise. Merck is conducting the Phase 3 Keylynk-001 trial investigating the efficacy of its leading oncology drug, Keytruda (pembrolizumab ...

Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

"For people living with ovarian cancer ... Gursel Aktan, Merck Research Laboratories' head of global clinical development. "KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus ...

Merck's phase III ovarian cancer study on a Keytruda regimen met its primary endpoint by showing a statistically significant and clinically meaningful improvement in progression-free survival.

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Merus N.V. (MRUS) stock surges after interim trial data from a cancer trial for the company's lead asset, petosemtamab with ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

Discussing ‘cure’ may risk oncologists’ credibility, should a patient’s ovarian cancer recur,” researchers wrote.

Ovarian cancer management is challenging due to high morbidity and mortality, often from late-stage diagnoses. Advances in tumor genomics have led to targeted therapies, improving outcomes for ...